Wild-type (senile) amyloidosis other imaging findings

Revision as of 18:39, 19 December 2019 by Sabawoon Mirwais (talk | contribs)
Jump to navigation Jump to search

Wild-type (senile) amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Wild-type (senile) amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Wild-type (senile) amyloidosis other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Wild-type (senile) amyloidosis other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wild-type (senile) amyloidosis other imaging findings

CDC on Wild-type (senile) amyloidosis other imaging findings

Wild-type (senile) amyloidosis other imaging findings in the news

Blogs on Wild-type (senile) amyloidosis other imaging findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Wild-type (senile) amyloidosis other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Other Imaging Findings

Nuclear Imaging

  • Bone-avid tracers, such as 99mTc-DPD (technetium-3,3-diphosphono-1,2-propanodicar-boxylic acid), 99mTc-PYP (technetium-pyrophosphate), and 99mTc-HMDP [technetium-hydroxymethylene diphosphonate (Tc-HMDP)] have been implicated to have high sensitivity and specificity for diagnosing cardiac amyloidosis and differentiating it from other cardiomyopathies with HFpEF.[1][2]


References

  1. Enrica Perugini, Pier Luigi Guidalotti, Fabrizio Salvi, Robin M. T. Cooke, Cinzia Pettinato, Letizia Riva, Ornella Leone, Mohsen Farsad, Paolo Ciliberti, Letizia Bacchi-Reggiani, Francesco Fallani, Angelo Branzi & Claudio Rapezzi (2005). "Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy". Journal of the American College of Cardiology. 46 (6): 1076–1084. doi:10.1016/j.jacc.2005.05.073. PMID 16168294. Unknown parameter |month= ignored (help)
  2. Sabahat Bokhari, Rachelle Morgenstern, Richard Weinberg, Mona Kinkhabwala, Demetrios Panagiotou, Adam Castano, Albert DeLuca, Andrew Kontak, Zhezhen Jin & Mathew S. Maurer (2018). "Standardization of (99m)Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis". Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 25 (1): 181–190. doi:10.1007/s12350-016-0610-4. PMID 27580616. Unknown parameter |month= ignored (help)